These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9120690)

  • 1. Franz Volhard Lecture 1996. Sodium transport inhibitors and hypertension.
    de Wardener HE
    J Hypertens Suppl; 1996 Dec; 14(5):S9-18. PubMed ID: 9120690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytochemical demonstration of an endogenous inhibitor of Na-K ATPase and its relationship to familial arterial hypertension].
    de Wardener H
    Nephrologie; 1987; 8(1):3-6. PubMed ID: 3035398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuresis and inhibition of Na+/K(+)-ATPase: modulation of response by physiological manipulation.
    McDougall JG; Yates NA
    Clin Exp Pharmacol Physiol Suppl; 1998 Nov; 25():S57-60. PubMed ID: 9809194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+-K+-ATPase.
    Haupert GT; Carilli CT; Cantley LC
    Am J Physiol; 1984 Dec; 247(6 Pt 2):F919-24. PubMed ID: 6095682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis.
    Hamlyn JM; Hamilton BP; Manunta P
    J Hypertens; 1996 Feb; 14(2):151-67. PubMed ID: 8728291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous Na+ transport inhibitor in human hypertension: further biochemical and chemical studies.
    Cloix JF; Crabos M; Grichois ML; Guicheney P; Meyer P
    Klin Wochenschr; 1987; 65 Suppl 8():146-53. PubMed ID: 3037183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-potassium pump inhibitor in the mechanism of one-kidney, one wrap hypertension in dogs.
    Pamnani MB; Swindall BT; Schooley JF; Ghai R; Haddy FJ
    Cell Mol Biol (Noisy-le-grand); 1999 Feb; 45(1):115-21. PubMed ID: 10099845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Na,K-ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis.
    Zhao N; Lo LC; Berova N; Nakanishi K; Tymiak AA; Ludens JH; Haupert GT
    Biochemistry; 1995 Aug; 34(31):9893-6. PubMed ID: 7632688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in plasma ouabainlike inhibitor of Na+, K+-ATPase with high sodium intake in patients with essential hypertension.
    Hasegawa T; Masugi F; Ogihara T; Kumahara Y
    J Clin Hypertens; 1987 Dec; 3(4):419-29. PubMed ID: 2839625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Canrenone: an effective antihypertensive in an experimental model of hypertension in which the active transport of sodium is diminished].
    Grichois ML; de Mendonça M; Wauquier I; Pernollet MG; Thormann B; Devynck MA; Meyer P; Garay RP
    Arch Mal Coeur Vaiss; 1986 Jun; 79(6):875-8. PubMed ID: 3099704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma endogenous sodium pump inhibitor in essential hypertension.
    Cloix JF; Devynck MA; Elghozi JL; Kamal LA; Lacerda-Jacomini LC; Meyer P; Pernollet MG; Rosenfeld JB; De Thé H
    J Hypertens Suppl; 1983 Dec; 1(2):11-4. PubMed ID: 6100615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of endogenous inhibition of Na-K-ATPase in human hypertension--sodium pump activity as a determinant of peripheral vascular resistance.
    Kramer HJ; Glänzer K; Sorger M
    Clin Exp Hypertens A; 1985; 7(5-6):769-82. PubMed ID: 2990771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium transport inhibitor from bovine hypothalamus.
    Haupert GT; Sancho JM
    Proc Natl Acad Sci U S A; 1979 Sep; 76(9):4658-60. PubMed ID: 228304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ouabain-like factors in hypertension: effects of ouabain and certain endogenous ouabain-like factors in hypertension.
    Yuan C; Manunta P; Chen S; Hamlyn JM; Haddy FJ; Pamnani MB
    J Cardiovasc Pharmacol; 1993; 22 Suppl 2():S10-2. PubMed ID: 7508010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salt, Na+,K+-ATPase and hypertension.
    Jaitovich A; Bertorello AM
    Life Sci; 2010 Jan; 86(3-4):73-8. PubMed ID: 19909757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal.
    Murrell JR; Randall JD; Rosoff J; Zhao JL; Jensen RV; Gullans SR; Haupert GT
    Circulation; 2005 Aug; 112(9):1301-8. PubMed ID: 16116051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous and exogenous cardiac glycosides and their mechanisms of action.
    Schoner W; Scheiner-Bobis G
    Am J Cardiovasc Drugs; 2007; 7(3):173-89. PubMed ID: 17610345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of endogenous brain "ouabain" in the sympathoexcitatory and pressor effects of sodium.
    Van Huysse JW; Leenen FH
    Clin Exp Hypertens; 1998; 20(5-6):657-67. PubMed ID: 9682921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ouabain, digitalis-like factors and hypertension.
    Hamlyn JM; Manunta P
    J Hypertens Suppl; 1992 Dec; 10(7):S99-111. PubMed ID: 1337913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ouabain-like and non-ouabain-like factors in plasma of patients with essential hypertension.
    Masugi F; Ogihara T; Hasegawa T; Kumahara Y
    Clin Exp Hypertens A; 1987; 9(7):1233-42. PubMed ID: 3040306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.